California 2023-2024 Regular Session

California Senate Bill SB70

Introduced
1/9/23  
Refer
1/18/23  
Introduced
1/9/23  
Introduced
1/9/23  
Refer
3/8/23  
Refer
1/18/23  
Refer
1/18/23  
Refer
3/8/23  
Refer
3/8/23  
Report Pass
4/17/23  
Refer
4/18/23  
Report Pass
4/17/23  
Report Pass
4/17/23  
Report Pass
5/18/23  
Refer
4/18/23  
Refer
4/18/23  
Engrossed
5/24/23  
Report Pass
5/18/23  
Report Pass
5/18/23  
Refer
6/1/23  
Engrossed
5/24/23  
Report Pass
6/28/23  
Refer
6/1/23  
Refer
6/1/23  
Refer
6/29/23  
Report Pass
6/28/23  
Report Pass
6/28/23  

Caption

Prescription drug coverage.

Impact

The implications of SB70 are significant for both patients and healthcare providers. By ensuring coverage continuity for off-label drug usage, particularly for chronic or life-threatening conditions, the bill aligns insurance policies with the evolving medical standards and the necessity for tailored patient treatment plans. However, since violations can lead to criminal charges against health plans, the responsibility for compliance is heavily placed on service providers and insurers, which could necessitate changes in their operating procedures.

Summary

SB70 aims to amend the Health and Safety Code and Insurance Code in California concerning prescription drug coverage. The bill specifically prohibits health care service plans and insurance policies from limiting or denying coverage based on off-label use of drugs that have previously been approved for coverage, provided certain conditions are met. This includes stipulations that the drug must be prescribed by a licensed health care professional for a critical or chronic condition and recognized for such use by relevant authorities. Importantly, the bill aims to eliminate additional cost-sharing for drugs previously approved, which can provide significant financial relief to patients dependent on ongoing treatments.

Sentiment

The sentiment surrounding SB70 appears to be mixed among stakeholders. Advocates argue that the bill empowers patients by aligning treatment decisions with medical practice rather than insurance guidelines, which could lead to better health outcomes. Conversely, critics may raise concerns regarding the potential financial burden on insurance providers and the healthcare system, as well as the implications of off-label prescriptions which can often be controversial.

Contention

Notably, the introduction and subsequent discussions on SB70 underscore broader tensions between patient needs and insurance company policies. Key points of contention likely arise around the balance of medical autonomy, where healthcare providers seek to utilize their professional judgement in prescribing treatments, against the procedural and financial restrictions typically imposed by insurance coverage. The bill will need close scrutiny and possibly adjustments to ensure that the goals of increasing access to necessary medications do not unintentionally compromise the financial viability of health care plans.

Companion Bills

No companion bills found.

Similar Bills

CA SB853

Prescription drug coverage.

CA AB260

Sexual and reproductive health care.

AZ SB1099

Supplemental breast exams; insurance; coverage

AZ SB1601

Breast examinations; cancer screenings; age

AZ SB1438

Health insurance coverage; insulin

AZ SB1216

Health insurance coverage; insulin

AZ HB2243

Insulin; health insurance coverage

AZ HB2841

Contraception; cost sharing prohibition